Dignitana expands intellectual property with new patent in Korea
Dignitana has received a Notice of Allowance from the Korean Intellectual Property Office for a patent titled “Scalp Cooling Apparatus, Method and System.”
Patent Application No. 10-2021-7017704 was submitted in 2021 and approved 31 December 2024. This filing expands on the previous Korean patent obtained by Dignitana in 2014 which was based on technology in Dignitana’s legacy C3 DigniCap scalp cooling system.
“Dignitana's IP portfolio provides a broad protection for our scalp cooling technology. We have an active IP strategy and have consistently worked to acquire rights in priority markets. This new patent in Korea brings additional value to the company and provides a solid foundation for strategic development in Asia,” said Fredrik Jonsson, CEO of Dignitana.
For More Information Contact
Fredrik Jonsson, CEO, fredrik.jonsson@dignitana.com +46 708766444
About Dignitana
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com.
Tags: